Wei Chen

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial

Ming Shi, Jiaojiao Wang, Hongming Huang et al. · Nature Communications · 2024 · 104 citations · Full text

Medicine, Immunology, Oncology +16

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial

Jieyun Xia, Hujun Li, Zhiling Yan et al. · Journal of Clinical Oncology · 2023 · 90 citations · Full text

Medicine, Immunology, Oncology +17

CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression

Qianqian Zhang, Ruixue Ma, Huimin Chen et al. · Journal of Oncology · 2023 · 28 citations · Full text

Life Sciences, Immunology, Oncology +17

Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐<scp>BCMA CAR</scp> T‐cell‐based therapy

Yuekun Qi, Hujun Li, Kunming Qi et al. · American Journal of Hematology · 2024 · 20 citations · Full text

Medicine, Oncology, Cancer Immunology +12

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma

Sha Ma, Jieyun Xia, Miao Zhang et al. · Blood · 2025 · 17 citations · Full text

Life Sciences, Genetics, Molecular Biology +17